Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
4-Factor prothrombin complex concentrates and factor VIII inhibitor bypass activity use in cardiac surgery.
Blood Coagul Fibrinolysis
November 2024
Department of Anesthesiology, Rush University Medical Center, Chicago, Illinois, USA.
Article Synopsis
- The study aimed to compare the occurrence of thromboembolic complications between two treatments, 4-factor prothrombin complex concentrate (4F-PCC) and factor VIII inhibitor bypassing activity (FEIBA), during cardiac surgery.
- Data was retrospectively analyzed from a university hospital involving patients who underwent cardiac procedures with cardiopulmonary bypass, focusing on various medical outcomes.
- Results indicated no significant difference in thromboembolic events, acute kidney injuries, or hospital stays between the two treatment groups, although variations in blood product usage were noted.
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study.
Cancer Immunol Immunother
November 2024
Department of Dermatology, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), University Hospital Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nuremberg (FAU), 91054, Erlangen, Germany.
Immune checkpoint inhibitor (ICI) therapies effectively treat a broadening spectrum of cancer entities but induce various immune-related side effects (irAEs). Recent reports suggest a correlation between ICI-induced systemic inflammation and thromboembolic events as well as an increased effectiveness by coadministration of anticoagulants. With cancer patients having a higher risk of thrombotic events per se, it is crucial to dissect and characterize the mechanisms that cause pro-coagulative effects induced by systemic tumor therapies and their potential interplay with anti-tumor response.
View Article and Find Full Text PDFNovel Insight into Inflammatory Pathways in Acute Pulmonary Embolism in Humans.
Arch Immunol Ther Exp (Warsz)
January 2024
Department of Internal Medicine and Cardiology, Center for Venous Thromboembolism Disease, Medical University of Warsaw, Warsaw, Poland.
Accumulating data have shown a pathophysiological association between inflammatory pathways and thrombosis. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and acute pulmonary embolism (APE), is a significant health burden. It involves not only hemodynamic disturbances due to the emboli occluding the pulmonary arteries, but also platelet activation, endothelial dysfunction, and "firing up" of the inflammatory cascade.
View Article and Find Full Text PDFImproved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease.
Blood Coagul Fibrinolysis
October 2024
Bleeding & Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI.
Article Synopsis
- Hemophilia A (HA) is characterized by frequent bleeding episodes, often requiring prophylactic factor VIII (FVIII) replacement to manage, especially when combined with von Willebrand disease (VWD), which is present in around 1% of the population.
- Co-existing HA and mild VWD can complicate effective treatment, and while traditional FVIII/VWF concentrates are used, some patients struggle with adherence due to the intravenous administration method.
- A new alternative, emicizumab, a non-factor subcutaneous therapy, has shown promise in reducing bleeding rates for patients with severe HA and VWD when traditional prophylaxis was insufficient, suggesting it could be a valuable option for better management.
Joint deficiency of coagulation factors VII and IX: a case report.
Blood Coagul Fibrinolysis
September 2024
Fundación Cardiovascular de Colombia, Piedecuesta, Santander, Colombia.
Article Synopsis
- A 23-year-old female with a history of bleeding issues presents with hematuria and metrorrhagia, and is found to have low hemoglobin (5.2 g/dl) and abnormal coagulation tests.
- Diagnosis includes uterine myoma, and she starts treatment with progesterone, antibiotics, and blood components while being monitored for factor levels.
- Despite initial improvement with recombinant factor VII, she faces complications requiring surgical intervention, with no similar cases found in literature to guide her treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!